Alpha-
Antitrypsin Deficiency, also called as AAT is a genetic disease that causes
serious lung diseases that leads to difficulty in breathing. The disease might
further spread to weaken the liver which would lead to jaundice. No cure has
been discovered so far but with effective treatment, AAT can be kept in control
without causing major respiratory difficulties. This disease is causes due to
inability of the liver to produce a protein called Alpha- 1 antitrypsin in
adequate quantities. Without this protein, irritants can easily attack the
lungs at a faster rate. Symptoms are hard to be detected until in 20s or 30s
when they slowly start surfacing. For a few people, AAT can lead to chronic
bronchitis and even chronic pulmonary obstructive disease. Many affected with
AAT often carry inhalers to ease their breathing just like in asthma. However,
no two cases of AAT are alike.
Neutrophil
elastase (NE) is capable of degrading a variety of structural proteins of the
extracellular matrix. Excessive NE activity have been detected in various lung
diseases, including bronchitis, pulmonary obstructive diseases. Endogenous
human NE is mostly neutralised by AAT. Congenital deficiency of AAT leads to
emphysema which can be treated with therapeutic AAT. Of recently, many
synthetic and recombinant elastase inhibitors have been identified and are in
the stage of development for clinical and preclinical purposes.
Pipeline
Review is an online portal that provides R&D new and online shop for
reports about research & development in the biopharmaceutical industry. Ken
Research’s Alpha-
Antitrypsin Deficiency - Pipeline Review, H2 2018 gives a snapshot of
the therapeutic landscape of the disorder. The report covers therapeutic
reviews based on their companies and research institutions based on their
information derived from industry- specific sources. It provides descriptive
drug profiles for the pipeline products which comprise, product description,
descriptive licensing and collaboration details, R&D brief, MoA & other
developmental activities. The companies involved in therapeutic development in
Alpha- Antitrypsin Deficiency are Adverum Biotechnologies Inc, Alnylam
Pharmaceuticals Inc, Applied Genetic Technologies Corp, Arrowhead
Pharmaceuticals Inc, AstraZeneca Plc, Carolus Therapeutics Inc, Editas Medicine
Inc, Grifols SA, Inhibrx LP, Intellia Therapeutics Inc, International Stem Cell
Corp, Kamada Ltd, Octapharma AG, OncBioMune Pharmaceuticals Inc, PlantForm
Corp, Promethera Biosciences SA, ProMetic Life Sciences Inc, rEVO Biologics
Inc, Santhera Pharmaceuticals Holding AG, Therapure Biopharma Inc and Z Factor
Ltd. The report will help in procuring important information on competitors and
their analysis to formulate R&D strategies to develop tactical initiatives
in the target demographic.
For more information, click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91-9015378249